PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the acceptance of its health outcomes study, the CAN-SCREEN model, for publication in the Journal of Medical Economics, highlighting the importance of combining clinically meaningful screening performance with high patient adherence in colorectal cancer (CRC) screening to optimize CRC-related health outcomes..

加利福尼亚州帕洛阿尔托——（商业新闻短讯）——领先的精准肿瘤学公司Guardant Health，Inc.（纳斯达克：GH）今天宣布接受其健康结果研究，即CAN-SCREEN模型，并将其发表在《医学经济学杂志》上，强调了将临床上有意义的筛查表现与结直肠癌（CRC）筛查中患者的高度依从性相结合以优化CRC相关健康结果的重要性。。

The CAN-SCREEN model addresses the significant limitations of existing models, which often assume absolute adherence to screening protocols. These assumptions fail to accurately predict population-level health outcomes, overlooking the real-world challenges and preferences of patients. Guardant Health's innovative model accounts for both clinical efficacy and adherence in determining CRC incidence and mortality rates..

CAN-SCREEN模型解决了现有模型的重大局限性，这些模型通常假定绝对遵守筛选协议。这些假设未能准确预测人口水平的健康结果，忽视了患者的现实挑战和偏好。Guardant Health的创新模型在确定CRC发病率和死亡率方面兼顾了临床疗效和依从性。。

A key benefit of Guardant Health’s blood-based screening test, Shield™, is the potential to reduce CRC-related mortality due to its high adherence. This non-invasive screening modality is designed to maximize patient adherence, offering a more accessible and preferable option than traditional methods.

Guardant Health基于血液的筛查测试Shield™的一个关键好处是，由于其高度依从性，有可能降低与CRC相关的死亡率。这种非侵入性筛查方式旨在最大程度地提高患者的依从性，提供比传统方法更容易获得和更好的选择。

By integrating this blood-based test into existing screening programs, the CAN-SCREEN model predicts a significant reduction in CRC-related deaths, particularly among previously unscreened populations. The model also predicts that patients screened with blood-based testing gained more life years, compared to those screened with FIT or mtsDNA..

通过将这种基于血液的测试整合到现有的筛查程序中，CAN-SCREEN模型预测CRC相关死亡的显着减少，特别是在先前未筛查的人群中。该模型还预测，与使用FIT或mtsDNA筛查的患者相比，使用血液检测筛查的患者寿命更长。。

“At Guardant Health, our mission is to enhance cancer detection and improve patient outcomes through innovative solutions,” said AmirAli Talasaz, Co-CEO of Guardant Health. “The CAN-SCREEN model's findings reinforce the critical role of adherence in CRC screening strategies. By leveraging our blood-based test, we are poised to substantially impact CRC screening adherence and ultimately save lives.”.

Guardant Health联合首席执行官阿米拉利·塔拉萨兹（AmiriTalasaz）表示：“在Guardant Health，我们的使命是通过创新解决方案增强癌症检测并改善患者预后。”。“CAN-SCREEN模型的发现强化了坚持CRC筛查策略的关键作用。通过利用我们的血液检测，我们准备对CRC筛查的坚持性产生重大影响，并最终挽救生命。”。

Guardant Health remains committed to advancing precision oncology through groundbreaking research and state-of-the-art diagnostic tools. The CAN-SCREEN model represents a pivotal step forward in optimizing CRC screening strategies, ensuring that more patients benefit from early detection and timely intervention..

Guardant Health仍然致力于通过开创性的研究和最先进的诊断工具来推进精准肿瘤学。CAN-SCREEN模型代表了优化CRC筛查策略的关键一步，确保更多患者从早期发现和及时干预中受益。。

About Guardant Health

关于Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.

Guardant Health是一家领先的精准肿瘤学公司，专注于维护健康，让每个人有更多的时间远离癌症。Guardant成立于2012年，通过先进的血液和组织测试、现实世界数据和人工智能分析，提供对疾病驱动因素的重要见解，正在改变患者护理并加速新的癌症治疗。

Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook..

Guardant测试有助于改善所有护理阶段的结果，包括筛查以早期发现癌症，监测早期癌症的复发以及晚期癌症患者的治疗选择。有关更多信息，请访问guardanthealth.com，并在LinkedIn、X（推特）和Facebook上关注该公司。。

References

参考文献

Forbes, S. P., Yay Donderici, E., Zhang, N., et al. (2024). Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence. Journal of Medical Economics, 1–40.

福布斯，S.P.，Yay Donderici，E.，Zhang，N。等人（2024）。与目前的筛查方式相比，基于血液的结直肠癌筛查的人群健康结果：来自包含纵向依从性的离散事件模拟模型的见解。医学经济学杂志，1-40。

https://doi.org/10.1080/13696998.2024.2382036.

https://doi.org/10.1080/13696998.2024.2382036.